Case Study: Replidyne: Setting the stage for a successful IPO

IGNITE established a guidance / strategy policy that communicated the companies growth strategy and established the foundation a successful IPO.

Initial Public Offering Case Study

The Challenge 

Replidyne, now part of Cardiovascular Systems, Inc. (NASD:CSII), retained IGNITE Consulting to position the company for a successful IPO.

The Solution

IGNITE helped Replidyne:

• Create compelling messaging;
• Establish a guidance policy/strategy;
• Effectively communicate the company’s growth strategy;
• Target priority investors, based on the company’s investment profile;
• Engage with bankers in the IPO allocation process; and
• Establish the foundation for an ongoing IR program, including developing IR website content, an efficient quarterly earnings process, and providing training on disclosure, trading regulations and policies.

Results/Key Highlights:

• Replidyne’s IPO was successfully completed and priced close to target, despite a tight IPO market;
• Management gained instant credibility with a focused guidance policy and an effective quarterly earnings process;
• The Company received favorable comments and ratings in analyst reports from  Merrill Lynch & Co., Morgan Stanley, Cowen & Co., Pacific Growth Equities, and others;
• Replidyne merged with Cardiovascular Systems, Inc. in February 2009.